volixibat

Small molecule

Phase 2topline reported

Evidence outlook

Primary Sclerosing Cholangitis: topline reported 2026-05-04

The sponsor reported topline results on 2026-05-04 (VISTAS Phase 2b met primary endpoint in PSC). The announcement is listed under Regulatory events.

Latest reported trial: VISTAS (NCT04663308) · Phase 2 · met primary endpoint · grade pending

Also in development:Primary Biliary Cholangitis · Phase 2

Featured evidence outside this drug's tracked markets:NCT02475317 · Healthy Volunteers · Phase 1 · completed · ungraded

Source for the program status

Company guidance: topline data expected first quarter of 2027 (Mirum Pharmaceuticals, Inc., 3 Nov 2026). “We expect topline data from our PBC study of volixibat in the first quarter of 2027.” Source ↗

Company guidance: regulatory filing expected first half of 2027 (NCT04663308; Mirum Pharmaceuticals, Inc., 3 Nov 2026). “We expect to submit a potential NDA to the FDA in the first half of 2027 for approval of volixibat for the treatment of pruritus due to PSC based on the VISTAS study and supporting data, but regulatory authorities still may not agree with our interpretation of the safety or efficacy data from the study and may not grant approval.” Source ↗

The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (4)
Primary Biliary Cholangitis
Primary Sclerosing Cholangitis
Other / comorbidity
NCT04718961 · Mirum Pharmaceuticals, Inc.
2021-01-04 – 2022-12-07 · Intrahepatic Cholestasis of Pregnancy
What this study did
NCT02787304 · Mirum Pharmaceuticals, Inc.
2016-10-24 – 2018-07-27 · Non-Alcoholic Steatohepatitis
What this study did
Phase 1 (1)
Other / comorbidity
NCT02475317 · Mirum Pharmaceuticals, Inc.
2015-06-01 – 2015-12-01 · Healthy Volunteers
What this study did

Competitive landscape

Other Ileal bile acid transporter (IBAT) drugs

maralixibat. Compare all 2 Ileal bile acid transporter (IBAT) drugs

1 other tracked programme targets this mechanism, 1 of them ahead of this one.

This drug's own stage for Primary Biliary Cholangitis: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Volixibat: this drugPhase 2Small moleculeIleal bile acid transporter (IBAT)not yet gradedNo reviewed efficacy summary in this indication
Elafibranor (Iqirvo)ApprovedSmall moleculePPAR-alpha/PPAR-deltaPartial signal
NCT04526665: Percentage of Participants With Response to Treatment Based on Cholestasis Response at Week 52 (At Week 52): Elafibranor 80 mg 50.9 Percentage of participants (95% CI 41.6 to 60.2) | Placebo 3.8 Percentage of participants (95% CI 1 to 12.8)
Maralixibat (Livmarli)
Approved(overall)
Small moleculeIleal bile acid transporter (IBAT)
Partial signal(overall)
No reviewed efficacy summary in this indication
Seladelpar (Livdelzi)ApprovedSmall moleculePPAR-deltaPartial signal
NCT06060665: Primary endpoint, composite ALP normalization at week 52: significantly more patients than placebo (Gilead, 2026-06-02).
NCT04620733: Composite biochemical response at Month 12 (ALP below 1.67 x ULN, ALP reduction of at least 15% and total bilirubin at or below ULN), seladelpar (n=128) vs placebo (n=65): 61.7% vs 20.0%; risk difference 41.7 percentage points (95% CI 27.7 to 53.4), p < 0.0001 (Cochran-Mantel-Haenszel; CT.gov posted results).
Saroglitazar (Lipaglyn)Phase 3Small moleculePPAR-alpha/PPAR-gammaPartial signal
NCT05133336: Primary composite biochemical response at 52 weeks: treatment difference 48.5% favouring saroglitazar 1 mg over placebo (P<0.001) (2025-08-29).
Pemafibrate (Parmodia)Phase 2Small moleculePPAR-alphanot yet gradedNo reviewed efficacy summary in this indication
SetanaxibPhase 2Small moleculeNOX1/4not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow volixibat to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
January 2027 (1)
Phase 2Primary Biliary CholangitisActive not recruiting
Est. primary completion 2027-01 · NCT05050136 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

4 May 2026Topline resultVISTAS Phase 2b met primary endpoint in PSC
Mirum Pharmaceuticals, Inc. · Source ↗